DAWES KAREN A — SEC Form 4 filings
SEC reporting owner CIK 1261506. 10 Form 4 filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-02-28 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 1,275 shares, $237,625 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: sale of 1,000 shares @ $193.35 ($193,350) in REPLIGEN CORP, filed 2024-02-28.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REPLIGEN CORP (RGEN) | Director | 7 | — | 2 legs · 1,275 sh · $237,625 | 10 |
| Barinthus Biotherapeutics plc. (BRNS) | Director | 3 | — | — | 8 |
Form 4 filings — DAWES KAREN A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Barinthus Biotherapeutics plc. (BRNS) | Disposition to issuer (D): 1,700 · Disposition to issuer (D): 34,328 (derivative) @ $0 · Disposition to issuer (D): 18,604 (derivative) @ $0 · Disposition to issuer (D): 19,197 (derivative) @ $0 · Disposition to issuer (D): 19,516 (derivative) @ $0 · Disposition to issuer (D): 20,174 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 995 @ $0 · Grant/award (A): 2,239 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | REPLIGEN CORP (RGEN) | Sale (S): 275 @ $161 | EDGAR |
| 2025-06-11 | 4 | Barinthus Biotherapeutics plc. (BRNS) | Grant/award (A): 20,174 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 973 @ $0 · Grant/award (A): 1,800 (derivative) @ $0 | EDGAR |
| 2024-08-19 | 4/A | REPLIGEN CORP (RGEN) | Holdings only — no transactions reported | EDGAR |
| 2024-06-14 | 4 | REPLIGEN CORP (RGEN) | Option exercise (M): 2,953 @ $67.71 · Option exercise (M): 2,953 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 803 @ $0 · Grant/award (A): 1,576 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Barinthus Biotherapeutics plc. (BRNS) | Grant/award (A): 19,516 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | REPLIGEN CORP (RGEN) | Option exercise (M): 4,626 @ $42.07 · Sale (S): 1,000 @ $193.35 · Option exercise (M): 4,626 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1261506 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →